Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 9;23(1):478.
doi: 10.1186/s12905-023-02630-7.

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV

Affiliations

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV

John C Chapola et al. BMC Womens Health. .

Abstract

Introduction: In 2018, the Malawi Ministry of Health adopted the recommendation to switch first-line antiretroviral therapy (ART) from an efavirenz (EFV)-based to a dolutegravir (DTG)-based regimen. Little is known about patients' experience during this transition. We conducted a qualitative study to explore DTG-related counselling challenges among providers of HIV care and factors influencing regimen switching or non-switching among women living with HIV in Lilongwe, Malawi.

Methods: Between February-July 2020, we recruited participants who took part in DTG counselling on reasons to switch, side effects, and benefits from two government health facilities providing HIV care: Area 18 health centre and Bwaila district hospital in Lilongwe, Malawi. We purposively sampled and interviewed 8 women living with HIV who remained on an EFV-based regimen after counselling, 10 women who switched to a DTG-based regimen, and 10 HIV care providers who provided counselling about ART switching. In-depth interviews were used to explore patient's perceptions of DTG, factors affecting the decision to switch, and both patient and provider experience with counselling. Interview data was coded for themes using inductive and deductive codes. Interviews were conducted until thematic saturation was achieved. Data matrices were used for analysis and thematic extraction.

Results: Most women in both groups were well versed on DTG's potential side effects and felt well counselled on the benefits of switching, such as quicker viral load suppression. Many women associated DTG with birth defects and expressed concern. However, the primary reason for not switching was concern with how the new medication would be tolerated, especially when they were satisfied with their current regimen. Almost all providers expressed difficulty providing DTG counselling. Primary reasons included feeling inadequately trained and/or not having resources to use during counselling, such as diagrams or brochures.

Conclusion: DTG counselling was well accepted by women; however, some felt that their concerns were not fully addressed. Providers reflected this sentiment in that they did not feel adequately trained or well-equipped to provide adequate counselling. Training on counselling for new ART regimens should be intensified and utilize patient-centered educational materials to address the concerns raised by both patients and health care providers.

Keywords: Adherence; Antiretroviral therapy; Dolutegravir; Efavirenz; Neural tube defects.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Dorward J, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. Jul. 2018;5(7):e400–4. 10.1016/S2352-3018(18)30093-6. - PMC - PubMed
    1. “Cutting the cost. Of south african antiretroviral therapy using newer, safer drugs - PubMed. https://pubmed.ncbi.nlm.nih.gov/28112085/ (accessed Feb. 14, 2022). - PubMed
    1. Raizes E, Hader S, Birx D. The US President’s emergency plan for AIDS Relief (PEPFAR) and HIV Drug Resistance: mitigating risk, monitoring impact. J Infect Dis. Nov. 2017;216:S805–7. 10.1093/infdis/jix432. Suppl 9.
    1. Organisation WH. “WHO. Dolutegravir (DTG) and the fixed dose combination (FDC) of teno fovir/lamivudine/dolutegravir (TLD),” 2018. https://www.who.int/hiv/pub/arv/DTG-TLD-arv_briefing_2018.pdf (accessed Feb. 14, 2022).
    1. Dorward J, Hamers RL. Dolutegravir in sub-saharan Africa: context is crucial. Lancet HIV. Feb. 2019;6(2):e72–3. 10.1016/S2352-3018(18)30331-X. - PubMed

Publication types